Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV Uterine Cancer

Research Question:
How well does the combination of pembrolizumab, paclitaxel, and carboplatin work compared with paclitaxel and carboplatin alone in treating patients with uterine (endometrial) cancer that is stage III, IV, or has come back (recurrent).

Basic Study Information

Purpose:
This phase III trial studies how well the combination of pembrolizumab, paclitaxel, and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III, IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

Location: University of Rochester Medical Center
Study Reference #: CGYE19140

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Barbara Kavinsky
Phone: (585) 273-3602
Email: Barbara_Kavinsky@URMC.Rochester.edu

Additional Study Details

Return to Search